mkc253

Peptideexperimental

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2007 (NCT00475371)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • glp-1 (7-36)amide
  • glp-1-(7-36) amide
  • glp-1a
  • glp-i (7-36)amide
  • glp-i (7-36)nh2
  • glucagon-like peptide 1 (7-36)amide
  • glucagon-like peptide-1(7-36 amide)
  • glucagon-like peptide i (7-36)amide
  • mkc253
  • mkc253
  • mkc253
  • mkc 253
  • mkc-253
  • proglucagon (78-107) amide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00642538Phase 1Feb 1, 2008MannKind Corp
NCT00475371Phase 1Apr 1, 2007MannKind Corp
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MannKind CorpFor profit2212007
1 organizations
Page 1 / 1